Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

Bristol Myers Squibb’s Opdivo plus Yervoy gets US FDA nod to treat adult and pediatric patients with mismatch repair deficient colorectal cancer: Princeton, N.J. Thursday, April ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

Prevent Cancer Foundation's 2025 Early Detection Survey showed that only about half of U.S. adults 21 years and older said ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Bristol Myers (BMY) announced that the U.S. Food and Drug Administration approved Opdivo plus Yervo as a first-line treatment of adult and ...